Drug pricing is pharma’s top concern in 2019

Drug pricing and reimbursement remains at the forefront of pharma executive minds as 2019 gets underway, according to a new industry survey. ... GlobalData’s poll also find that while Brexit and political uncertainty in the US were big stories in 2018,

After December slump, what’s in store for biotech in 2019?

the difficulties biotech companies have achieving profitability once their products reach the market, and of course issues such as drug pricing and the sustainability of economic growth.

Beneluxa: the future of European market access?

The agencies are also reusing each other’s drug assessment reports in order to cut out unnecessary duplication. ... Meanwhile, there are some major concerns for pharma, too: some stakeholder groups want to use the legislation to enforce complete

Better together when buying medicines? Taking stock of the BeNeLuxA initiative

Apply that to the fragmented and diverse landscape of drug pricing and reimbursement in Europe and the reality becomes a lot more complicated. ... There is MEDEV too, an informal cooperation on the assessment, pricing and reimbursement of medicines in

Vertex rises on data for cystic fibrosis triple therapy

Company will wait for further results before filing. Vertex Pharma has unveiled the first phase 3 data from its highly-anticipated three-drug combination for cystic fibrosis (CF), setting up a ... The interim results come from two studies of its two-drug

Deal Watch October 2018

The Health Secretary, Alex Azar, has promised more to come on “fixing” drug pricing and introducing transparency into drug prices, and in the present political climate that can only be good ... Endocyte’s lead clinical product is 177Lu‐PSMA‐617,

Trust me, I’m from pharma

However, controversies around drug pricing – fuelled by the unhelpful interventions of Martin Shkreli as the pin-up boy for big, bad pharma – have undermined progress and reinforced the view that the ... Individual companies are doing their bit too.

Patient outcomes in practice: delivering value that transforms lives

Providers, payers and manufacturers all have a role in achieving value, with increasing ethical pressure on drug pricing and resultant innovative, outcomes-based pricing models.

Drug pricing

Risky business for pharma

Chan Lee, North America general counsel, Sanofi, explained: “Drug pricing is a significant risk in our industry, particularly in the US.” Lee also cited “scrutiny of manufacturer interactions with payers, patients, ... PD Villareal, senior vice

Pfizer’s Emms takes up ABPI presidency

Emms is no stranger to these issues, having served on the ABPI board and taken part in the negotiations over the future of drug pricing in the UK. ... He has not been afraid to criticise the outcomes of these discussions too, saying in November that the

Bayer's Martin Hesse moves to Daiichi Sankyo Europe

Commenting on the environment in which he starts at Daiichi, Hesse said securing the company's profitability and competitiveness in the light of drug pricing interventions will a major challenge.

Pricing's Point Man

In the wake of the publication of the second edition of 'The Price of Global Health', Ed Schoonveld talks to William Looney. Pharm Exec Editor-in-Chief William Looney talks to Ed Schoonveld about the key policy and management issues around market

Turkey: Identifying the Growth Drivers

This sector is dominated by pro-innovative drug prescribing physicians as well as a patient population who is willing to pay for a higher “quality” healthcare. ... Overall, while the public sector is characterised today byaggressive drug pricing

Article: The Colombia Conundrum

drug pricing, as well as a streamlining of the essential drug list to remove some of the higher cost drugs. In a move to combat corruption, the EPS are set to ... This is exemplified by Sanofi’s 2012 acquisition of Genfar, which has resulted in the

Ed Schoonveld - new article

Following the publication of the new edition of The Price of Global Health, Ed Schoonveld writes about the industry's need for new drug pricing model. ... Does the drug industry need a new pricing model? Read Ed Schoonveld's article here  . The new

New Schoonveld Book now out!

Written by global drug pricing expert Ed Schoonveld, The Price of Global Health, second edition, is the most comprehensive book on global pharmaceutical pricing available today. ... The book offers a thorough and straightforward exploration of the drug